Avalo Therapeutics AVTX Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's interest coverage?
- Avalo Therapeutics (AVTX) reported interest coverage of -19.8× in Q1 2026.
- How has Avalo Therapeutics's interest coverage changed year-over-year?
- Avalo Therapeutics's interest coverage decreased by 71.0% year-over-year, from -11.6× to -19.8×.
- What is the long-term trend for Avalo Therapeutics's interest coverage?
- Over 2 years (2020 to 2025), Avalo Therapeutics's interest coverage has grown at a -87.5% compound annual growth rate (CAGR), from -1,071.2× to -16.8×.
- What does interest coverage mean?
- Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.